Field evaluation of the efficacy and safety of Forcyl (R) Swine in the the treatment of SRD in naturally infected pigs
Actinobacillus pleuropneumoniae (APP) is a causative agent of porcine pleuropneumonia, causing significant economic losses worldwide. Antibiotherapy is the best approach with respect to animal welfare and consumer protection, especially when the treatment is efficacious and at the same time does not support the development of anitimiccrobial resistance in the target bacteria and commensal flora. This study evaluated the efficacy and safety of Forcyl(R) Swine, a single-injection short acting marbofloxacin, for the treatment of swine respiratory disease (SRD) associated with APP.
DATE »
06.05.2015
AUTHORS »
Grandemange, E.; Perrin, P.; Cvejic, D (Klifovet AG).; Haas, M. (Klifovet AG); Hellmann, K. (Klifovet AG)
PUBLISHED »
7th European Symposium of Porcine Health Management, Nantes, France, April 22-24, 2015.